Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Aminoguanine SCHEMBL21761 | 0.74 | PNP (1.00) | PNPMAPTTHRBKDM4EMEN1 | |
| SCHEMBL546662 | 0.73 | XDH (0.35) | FGFR1FGFR2 | |
| SCHEMBL22883 | 0.71 | PNP (0.73) | PNPMAPTTHRBKDM4EMEN1 | |
| SCHEMBL443984 | 0.69 | KDM4E (0.47) | PNPMAPTTHRBKDM4EALDH1A1 | |
| SCHEMBL5857483 | 0.68 | GDA (0.57) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL20577 | 0.67 | PNP (0.73) | PNPMAPTTHRBKDM4EMEN1 | |
| SCHEMBL9116 | 0.67 | PNP (0.73) | PNPMAPTTHRBKDM4EMEN1 | |
| SCHEMBL2698213 | 0.67 | DPP4 (0.47) | — | |
| 8-Azaguanine SCHEMBL26817 | 0.67 | PNP (0.61) | PNPMAPTTHRBKDM4EMEN1 | |
| SCHEMBL844207 | 0.67 | PNP (0.73) | PNPMAPTTHRBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38416-E1 | NUCLEOTIDE BASES COMPRISING PYRAZOLO(3,4-D)PYRIMIDINES USED FOR MEDICAL DIAGNOSIS, THERAPY, HYBRIDIZATION, ANTISENSE AGENTS OR REPORTER MOLECULES | EPOCH BIOSCIENCES, INC. | 2004-02-03 | — | — | US | claimed |
| US-5824796-A | MEDICAL DIAGNOSIS WITH TARGET DNA OR RNA FOR ENZYME INHIBITORS | EPOCH PHARMACEUTICALS, INC. (US) | 1998-10-20 | — | — | US | claimed |
| EP-0472648-A4 | CROSSLINKING OLIGONUCLEOTIDES | — | 1992-09-16 | — | — | EP | claimed |
| EP-0472648-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1992-03-04 | — | — | EP | claimed |
| WO-1990014353-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1990-11-29 | — | — | WO | claimed |
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024136899-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137864-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240117363-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| EP-4346904-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-1996040711-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0661979-A4 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION. | MICROPROBE CORP (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0661979-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994017092-A1 | BIFUNCTIONAL CROSSLINKING OLIGONUCLEOTIDES ADAPTED FOR LINKING TO A DESIRED GENE SEQUENCE OF INVADING ORGANISM OR CELL | MICROPROBE CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1993003736-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| EP-0472648-A4 | CROSSLINKING OLIGONUCLEOTIDES | — | 1992-09-16 | — | — | EP | disclosed |
| EP-0472648-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1990014353-A1 | CROSSLINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | IL2, IL2RA, CD22 | PNP 4686/4885MAPT 3868/4885THRB 726/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | PNP 3/4885MAPT 2787/4885THRB 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.